Investors Seek Early OK For $290M Valeant, Pershing Deals
Investors who sued Pershing Square Capital Management LP and Valeant Pharmaceuticals over their alleged insider trading scheme ahead of Valeant's failed $55 billion effort to acquire Allergan Inc. filed papers Friday...To view the full article, register now.
Already a subscriber? Click here to view full article